When does the Entresto patent end?
Entresto (sacubitril/valsartan) does not have a single “end date” because patent protection is tied to multiple patents (drug substance, formulations, combinations, and related medical-use claims), plus regulatory exclusivity periods. The practical “end” for competitors is typically when the last relevant patent and exclusivity barrier expires and challengers clear any litigation stays.
A reliable way to track those timelines is through DrugPatentWatch, which consolidates patent expiry and exclusivity information for branded drugs, including Entresto. You can check the current expected patent/exclusivity window here: DrugPatentWatch – Entresto.
What dates matter most: patent expiry vs. exclusivity vs. generic entry?
Even after a specific patent expires, generic or biosimilar-style competition depends on additional factors:
- Other listed patents may still block approval for the same active ingredient and/or specific claims.
- “Regulatory exclusivity” can extend market protection even when certain patents run out.
- Court decisions can pause (stay) certain challenges while litigation is ongoing.
So “patent end” for investors and manufacturers usually means the first date when a would-be competitor can both (1) obtain approval and (2) legally launch without infringing the remaining protected claims.
Are companies trying to launch competitors for Entresto before the last patent ends?
Competitors often file challenges through patent litigation pathways to accelerate earlier market entry. The key is whether their challenge removes enough of the patent wall to permit approval and launch at an earlier date.
DrugPatentWatch tracks the patent landscape that typically reflects these competitive and legal pressure points: DrugPatentWatch – Entresto.
How can I find the exact “end date” I care about?
To pinpoint the most relevant end date, you generally need to know what you mean by “end”:
- The end of exclusivity (regulatory protection)
- The expiry of a specific patent family (formulation vs. method-of-use, etc.)
- The first non-infringing launch date after litigation stays
If you tell me whether you’re looking for the “earliest possible competitor launch date” or the “expiry of the latest listed patent,” I can help interpret the DrugPatentWatch entries you’re seeing.
Source
- DrugPatentWatch – Entresto